Human Neural Stem Cell Therapy for Chronic Ischemic Stroke – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
Human Neural Stem Cell Therapy for Chronic Ischemic Stroke
Genetic Engineering & Biotechnology News Chronic disability after stroke represents a major unmet neurologic need. ReNeuron’s development of a human neural stem cell (hNSC) therapy for chronic disability after stroke is progressing through early clinical studies. A Phase I trial has recently … |
|
Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
Dove Medical Press Methods: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48–72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular … |
Forbes |
Study That Claims CRISPR Causes Unwanted Mutations Is Probably Wrong
ScienceAlert If that was the case, we would have to seriously reconsider the safety of CRISPR, especially when used on humans. But now a paper has been published online claiming it was all a mistake, and the authors of the original study were doing a “disservice to … CRISPR Gene Editing Controversy: Does It Really Cause … – ForbesForbes Controversial CRISPR-causes-unwanted-mutations study possibly …Genetic Literacy Project |
|
Study That Claims CRISPR Causes Unwanted Mutations Is Probably Wrong
ScienceAlert If that was the case, we would have to seriously reconsider the safety of CRISPR, especially when used on humans. But now a paper has been published online claiming it was all a mistake, and the authors of the original study were doing a “disservice to … |
Globalnews.ca |
Researcher warns of risks associated with unregulated stem cell treatments
Globalnews.ca A researcher at the University of Alberta has a warning about the dangers of unregulated stem cell treatments. While he’s a believer in the science behind stem cell therapy, Canada research chair in health law and policy Tim Caulfield told the Alberta … |
Madison.com |
Billions of Dollars on the Line for Celgene With These 3 Small Biotechs
Madison.com In 2015, Celgene forged another relationship with a small biotech specializing in treating cancer via chimeric antigen receptor T–cell (CAR-T) therapies — Juno Therapeutics. The deal involved collaboration on several of Juno’s immunotherapy candidates. |